Hickman T, Choi E, Whiteman K, Muralidharan S, Pai T, Johnson T, et al. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity. PLoS ONE. 2022;17:e0266980 pubmed publisher

Dalla Pietà A, Cappuzzello E, Palmerini P, Ventura A, Visentin A, Astori G, et al. Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. J Immunother Cancer. 2021;9: pubmed publisher

Lake C, Voss K, Bauman B, Pohida K, Jiang T, Dveksler G, et al. TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8+ T cells in conjunction with CEACAM1. Cell Death Dis. 2021;12:400 pubmed publisher

Tseng H, Xiong W, Badeti S, Yang Y, Ma M, Liu T, et al. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020;11:4810 pubmed publisher

Seitz C, Schroeder S, Knopf P, Krahl A, Hau J, Schleicher S, et al. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncoimmunology. 2020;9:1683345 pubmed publisher

Marotte L, Simon S, Vignard V, Dupré E, Gantier M, Cruard J, et al. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes. J Immunother Cancer. 2020;8: pubmed publisher

Lynn R, Weber E, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576:293-300 pubmed publisher

Reed J, Preston Hurlburt P, Philbrick W, Betancur G, Korah M, LUCAS C, et al. The receptor for advanced glycation endproducts (RAGE) modulates T cell signaling. PLoS ONE. 2020;15:e0236921 pubmed publisher

Gee M, Han A, Lofgren S, Beausang J, Mendoza J, Birnbaum M, et al. Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell. 2018;172:549-563.e16 pubmed publisher